Pilot Study Shows That Investigational Interconnected Diabetes Management Solution From Ascensia Significantly Reduced HbA1c In People With Type 2 Diabetes

June 18 , 2019
PHC Holdings Corporation

TOKYO, June 18, 2019 - PHC Holdings Corporation (headquarters: Tokyo, Japan) announces that at the American Diabetes Association’s 79th Scientific Sessions (ADA 2019), Ascensia Diabetes Care, a global leader in diabetes care, presented clinical research that demonstrates that people with type 2 diabetes who participated in the study significantly lowered HbA1c while using its investigational Interconnected Diabetes Management Solution (IDMS), suggesting it has the potential to improve self-care and glycemic control. Ascensia Diabetes Care is a wholly-owned subsidiary of PHC Holdings Corporation, headquartered in Basel, Switzerland.

The study found that the use of Ascensia’s investigational IDMS was associated with a significant decrease in HbA1c levels in people with type 2 diabetes, independent of any changes to diabetes medication, suggesting that the solution could lead to improved self-care and better glycemic control. As the primary endpoint, mean HbA1c significantly decreased by 0.43%, from 8.44% at the start to 8.01% after 12 weeks. These data are the first indication of clinically meaningful results from the use of this IDMS and suggest that the solution has the potential for benefit in the management of type 2 diabetes. The study was presented as a poster*1 on Sunday June 9 at the ADA 2019 in San Francisco by Dr. Leslie J Klaff of the Rainier Clinical Research Center, Renton, WA, USA.

Ascensia’s investigational solution is designed to provide additional support for adults with diabetes by enabling them to more effectively manage their condition. It uses a combination of remote behavioral coaching from a Certified Diabetes Educator (CDE) and a mobile application to support people with type 2 diabetes. The CDE is able to use the person’s own data to customize their coaching guidance, providing them with actionable information that can support their own individual self-management.

The solution allows the CDE to suggest guidance-directed tasks that support users to make informed behavioral changes and improve self-management. Taking a holistic approach to diabetes management, calls from the CDE and subsequent monitoring helps people with behavioral interventions to improve blood glucose monitoring, food choices, activity levels, stress and sleep.

Dr. Leslie Klaff, lead author, explained: “This research is the first study to demonstrate a benefit for this IDMS and indicates the potential of this solution for the management of type 2 diabetes. The combination of interaction with a human guide together with the app is an exciting development in diabetes management solutions. The IDMS in this study allowed individuals together with their guide to decide the lifestyle changes that might work for them. Based on these decisions, the individual could then determine how the app could best be used and they were coached throughout by the guide.”

He added, “This study indicates that these two components appear to form an effective tool to support behavioral change and improve glycemic control by enabling people with diabetes to make small but impactful lifestyle adjustments. There is potential for substantial clinical benefit by using this type of technology-led approach and further research with longer duration studies is needed to better understand the effect size of this digital intervention.”

The study lasted for 12 weeks and was designed as a single-arm pilot study. It included 58 participants, who previously had not achieved glycemic control, and regular blood glucose data was captured using a wireless enabled CONTOUR®NEXT ONE*2 blood glucose smart meter.

Russ Newsome, Global Head of Interconnected Diabetes Management, Ascensia Diabetes Care said: “There is an increasing drive from the diabetes community for new digital solutions that can support self-management of type 2 diabetes. We are excited by the results we see in this study and look forward to conducting further research that investigate the effectiveness of this solution. We are pleased to continue our involvement in cutting-edge research in the digital space that help further our understanding of how these solutions can support the management of diabetes and help to improve lives.”

Ascensia’s investigational IDMS is currently only being studied and developed for use in the United States.

*1. Klaff, L., Maier, T., Richardson, J. and Pardo, S., A Pilot Study to Evaluate the Utility of an Interconnected Diabetes Management Solution in People with T2D. Poster presented at the American Diabetes Association’s 79th Scientific Sessions, San Francisco, California, USA, 2019
*2. Wireless-enabled blood glucose monitoring system that links to a smart mobile device via Bluetooth® connectivity. This model and its application are available only in overseas markets.

*Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.
The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license.

About PHC Holdings Corporation

Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with its products and services used in more than 125 countries. Subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnosis, life sciences and healthcare IT.

For further information, please visit

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes

Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd(currently, PHC Holdings Corporation.) Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website

Media contact

Corporate Communications Group
PHC Holdings Corporation